NeOnc's Intranasal NEO100 Hits 48.9% Six-Month PFS in Recurrent IDH1-Mutant Glioma
核心洞察
NeOnc reported topline Phase 2a results for intranasal NEO100 in recurrent or progressive Grade III and IV IDH1 (搜索)-mutant glioma, with six-month progression-free survival of 48.9% versus a 20% prespecified standard-of-care benchmark.
The 24-patient open-label study reported a one-sided p-value of 0.0047, median overall survival of 26.09 months and six-month overall survival of 86.7%, with no major toxicities observed.
The six-month PFS estimate carries a wide confidence interval of 26.3% to 68.1%, and the trial used a historical benchmark rather than a concurrent randomized control group.
NeOnc Technologies Holdings (搜索) reported topline results from the Phase 2a portion of the NEO100-01 study on August 12, 2026, testing an intranasal formulation of purified perillyl alcohol in patients with recurrent or progressive Grade III and Grade IV IDH1 (搜索)-mutant glioma. The 24-patient, open-label study reported six-month progression-free survival of 48.9%, against a 20% benchmark for standard of care specified in the study design. The company reported a one-sided p-value of 0.0047. Median overall survival was 26.09 months, and overall survival at six months was 86.7%.
The program addresses a setting where treatment options narrow. Patients with recurrent high-grade glioma (搜索) may have already undergone surgery, radiation and temozolomide, and the central problem is not only identifying a molecule that can kill cancer cells but delivering an effective amount of it to the right place without unacceptable toxicity elsewhere.
Delivery as the Therapeutic Strategy
NEO100 is designed to bypass the blood-brain barrier rather than cross it from the bloodstream. The drug is delivered through the nose and is intended to reach the brain through the olfactory pathway, making drug delivery itself part of the therapeutic strategy.
The blood-brain barrier has long functioned as both a biological defense system and a drug-development obstacle. It protects the brain from potentially harmful circulating substances, but that protection also prevents many cancer drugs from reaching tumors at therapeutically useful concentrations. Researchers have pursued molecular engineering, nanoparticles, focused ultrasound and convection-enhanced delivery to circumvent or temporarily alter the barrier. An intranasal approach instead attempts to exploit an anatomical route around it.
The company says the recommended regimen is intranasal dosing four times daily in 28-day cycles, which allows patients to self-administer at home. The Phase 2a report said no major toxicities were observed and that adverse events were predominantly low-grade. A treatment that avoids hospitalization, infusion infrastructure or repeated invasive procedures carries a burden beyond its pharmacology, and for patients living with recurrent brain cancer, avoiding another procedure can be clinically meaningful even before efficacy is settled.
Long-Tail Responses and an Unvalidated Biomarker Hypothesis
Five of the 24 patients remained on treatment at the time of the readout. One patient had an ongoing partial response beyond 114 days, and another was reported to have remained progression-free for roughly 19 months. Whether that long tail reflects a biologically distinct subgroup, unusual sensitivity among IDH1 (搜索)-mutant patients, or simply the disproportionate visibility of individual outcomes in a small sample remains to be determined.
NeOnc pointed to a biological rationale involving IDH1 (搜索)-mutant tumors, saying earlier Phase 1 experience had shown long-term survivors carrying an IDH1 mutation. That remains a hypothesis rather than a validated predictive biomarker.
Statistical Uncertainty and the Path to Registration
The Phase 2a study compared its primary endpoint with a prespecified historical benchmark rather than a concurrent randomized control group, and the reported six-month PFS estimate has a confidence interval of 26.3% to 68.1%. The design leaves substantial uncertainty around an estimate derived from a small population, and a next step would be demonstrating the effect in a randomized trial that establishes whether nose-to-brain delivery is superior to conventional systemic treatment.
NeOnc has said it intends to request a Type B meeting with the FDA to discuss a potential registrational path for NEO100 in recurrent IDH1 (搜索)-mutant high-grade glioma. The regulatory question will not be limited to whether the Phase 2a result cleared its prespecified statistical benchmark, but whether the design, population, endpoint and magnitude of the observed effect provide an adequate foundation for the next development step.
Financing the CNS Portfolio
NeOnc announced a USD 15 million registered direct offering on September 9, 2026, with proceeds directed toward advancing its two central nervous system cancer therapeutics through ongoing Phase II trials. The offering was priced at-the-market under Nasdaq rules at USD 4.20 per share, covering 3,571,430 shares of common stock to new and existing healthcare-focused institutional investors. Each share was accompanied by a warrant to purchase one additional share at USD 4.20, exercisable immediately and expiring five years from issuance. Pre-funded warrants were available in lieu of common stock at USD 4.1999 per unit. Gross proceeds are estimated at USD 15 million before placement agent fees, with Roth Capital Partners and A.G.P./Alliance Global Partners acting as co-placement agents.
NeOnc's two lead assets are NEO100, an intranasal perillyl alcohol formulation, and NEO212, a temozolomide-perillyl alcohol conjugate. Both are in Phase II trials for malignant gliomas and hold FDA Fast-Track status. The company holds an exclusive worldwide patent license from the University of Southern California covering NEO100, NEO212 and related compounds, with patent protections extending to 2038.
If larger and better-controlled studies reproduce the Phase 2a signal, the implications could extend beyond perillyl alcohol or NeOnc by strengthening the case for intranasal delivery as a CNS development strategy. The Phase 2a data have not changed brain-cancer care, but they have generated a signal that warrants controlled investigation.